May 22, 2024

  * Philips wearable ePatch and AI analytics platform help detect potentially
    life-threatening irregular heartbeats

* The solution helps University Hospital Vall d'Hebron achieve reduced average length of stay, relieve emergency room pressure, and reduce costs
Amsterdam, the Netherlands, and Madrid, Spain - Royal Philips
(http://www.philips.com/newscenter) (NYSE: PHG, AEX: PHIA), a global leader in
health technology, today announced the successful nationwide rollout of its
ambulatory cardiac monitoring service in Spain using its unique wearable ePatch
(https://www.gobio.com/epatch/) paired with its AI-driven Cardiologs
(https://cardiologs.com/) analytics platform. 14 Spanish healthcare providers
across the country are now using the company's ePatch extended wear Holter
monitors to detect life-threatening heart arrhythmias such as atrial
fibrillation (AF). The solution has been proven to detect heart arrhythmias
missed by traditional Holter monitors, enhance patient comfort, improve care
access, and potentially better clinical outcomes, in addition to reducing
overall costs.
Philips' ePatch provides reliable data for up to 14 days of continuous
monitoring. When paired with Philips' AI-driven Cardiologs
(https://cardiologs.com/) analytics platform, the solution empowers the
hospitals' cardiology and neurology teams with an end-to-end solution that
enhances their ability to detect and diagnose AF - a potentially life-
threatening (1) cardiac arrhythmia and also the world's most common. AF
significantly increases the risk of stroke, dementia, and heart failure, yet
often goes undetected due to its lack of noticeable symptoms and infrequent
occurrence intervals.
"The key advantage for healthcare professionals lies in its user-friendly
interface and high-quality 14-day continuous recording capabilities," said Dr.
Jorge Pagola, Neurologist Postdoctoral Researcher at University Hospital Vall
d'Hebron, Barcelona, Spain. "Applied as a chest patch in just a few minutes, it
seamlessly integrates an analysis program, facilitating swift examination of
recordings. Thanks to its AI-based analysis assistant, AF events can be
classified for rapid review by our team. Patients experience enhanced comfort as
they are free from cumbersome cables of the conventional Holter, allowing them
to dress, shower, and carry out their daily activities without any hindrance."
Dr. Jorge Pagola further explains, "Using the ePatch program, we expedited
hospital discharge for 80 patients in 2023. This initiative led to a reduced
average length of stay, relieved emergency room pressure, and an estimated total
cost reduction of EUR 28.800 in 2023 (2)."
Pilot programs in major hospitals across Spain
In addition to Hospital Vall d'Hebron, where Philips' ePatch is being used to
detect post-discharge AF in patients, pilot projects demonstrating the device's
effectiveness in cardiology and neurology are being conducted at other major
hospitals in Madrid, Barcelona, Bilbao, Alicante, Madrid, Cadiz, and Navarra
(3). Applications include monitoring patients for AF after cardiac ablation
therapy or heart valve replacement procedures, and studies of the link between
magnesium insufficiency and AF.
In some Spanish hospitals, the ease-of-use and cost benefits of Philips ePatch
are helping reduce waiting lists that built up during the COVID-19 pandemic,
making a tangible difference to people's access to care. In total, more than
1500 patients are currently being monitored with Philips ePatch devices in
Spain.
"This innovative new service allows clinical teams to conveniently monitor
patients as they go about their everyday activities for extended periods of
time, collecting the real-life data that helps reveal the patient's true
condition," said Miquel Barras, Ambulatory Monitoring & Diagnostics Lead for
Philips in Spain.
In a recent US study comparing the diagnostic abilities of 7-day and 14-day
monitoring with Philips' extended wear ePatch compared to conventional 24-hour
Holter monitoring, the ePatch detected 2x more clinically significant heart
arrhythmias during 7 days of monitoring and more than 2.5x as many over 14 days
(4).
(1) Heart.org (https://www.heart.org/en/health-topics/atrial-fibrillation/what-
is-atrial-fibrillation-afib-or-af)
(2) Data on file in hospital Vall d'Hebron
(3) Madrid: Hospital Universitario Fundación Jiménez Díaz, Hospital
Universitario Infanta Elena, Hospital de La Princesa, University Hospital
Quironsalud Madrid, Hospital Universitario Rey Juan Carlos. Barcelona: Vall
d'Hebron University Hospital, Hospital Clínic de Barcelona, Hospital de Sant
Joan Despí Moisès Broggi, Hospital Sant Joan de Déu Barcelona, Hospital
Universitari de Bellvitge, Hospital de Sant Pau. Bilbao: Hospital Universitario
Cruces. Alicante: Hospital General Universitario de Elche. Cadiz: Hospital
Universitario De Jerez. Navarra: Hospital General de Navarra.
(4) Parikh, P, Grigoriadis, C, Dunn, A. et al. Diagnostic Yield of 24-hour
Holter vs 7-day and 14-day ePatch Extended Wear Holter. J Am Coll Cardiol. 2023
Mar, 81 (8_Supplement) 149. Research conducted by Philips ECG Solutions.
https://doi.org/10.1016/S0735-1097(23)00593-4
For further information, please contact:
César García Requena
Philips Ibérica
Tel: +34 670 264 471
Email: cesar.garcia.requena@philips.com (mailto:cesar.garcia.requena@philips.com)
Joost Maltha
External Relations
Tel: +31 6 10 55 8116
Email: joost.maltha@philips.com (mailto:joost.maltha@philips.com)
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company
focused on improving people's health and well-being through meaningful
innovation. Philips' patient- and people-centric innovation leverages advanced
technology and deep clinical and consumer insights to deliver personal health
solutions for consumers and professional health solutions for healthcare
providers and their patients in the hospital and the home. Headquartered in the
Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-
guided therapy, monitoring and enterprise informatics, as well as in personal
health. Philips generated 2023 sales of EUR 18.2 billion and employs
approximately 69,100 employees with sales and services in more than 100
countries. News about Philips can be found at www.philips.com/newscenter
(http://www.philips.com/newscenter).
Â